For example, the neutralizing humanized anti-IL-10 mAb, BT063, is being investigated in a phase 2 trial (NCT02554019) for the treatment of systemic lupus erythematosus (SLE). This evidence concerns the gene IL10 and systemic lupus erythematosus.